Arrowhead Pharmaceuticals, Inc.
Investor Relations Department
225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: ARWR	
Last Trade:	1.55
Trade Time:	4:00 PM ET Apr 28, 2017
Change:	-0.01 (-0.641%)
Day Range	1.50 - 1.59
52-Week Range	1.20 - 8.22
Volume	641,047

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

… (more)

Stock Performance



Press Releases [View all]

Apr 26, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results

Apr 24, 2017
Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™

Apr 20, 2017
Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™

Apr 5, 2017
Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™

Mar 23, 2017
Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

Upcoming Events [View all]

May 3, 2017 4:30 PM ET
Arrowhead Fiscal 2017 Second Quarter Results

Financials [View all]

First Quarter Financial Results

Dec 14, 2016
Annual Report (10-K)

Feb 1, 2017
Proxy Statement (DEF 14A)

Feb 6, 2017
Quarterly Report (10-Q)

Aug 9, 2016
Quarterly Report (10-Q)

May 10, 2016
Quarterly Report (10-Q)